Thermo Fisher Scientific stock rises toward $631 as TMO heads into Jan. 29 earnings

Thermo Fisher Scientific stock rises toward $631 as TMO heads into Jan. 29 earnings

New York, January 26, 2026, 13:10 EST — Regular session underway

  • Thermo Fisher shares climbed roughly 0.8% by midday, bouncing back after an initial drop
  • Attention shifts to Thursday’s release of fourth-quarter and full-year results, along with the 2026 outlook
  • Options markets suggest a bigger-than-usual swing ahead of the report

Shares of Thermo Fisher Scientific Inc climbed on Monday, with TMO trading up 0.8% at $631.24 by midday in New York. The stock started the day lower, fluctuating between $623.51 and $631.36.

Thermo Fisher now trades roughly 2% under its 52-week peak of $643.99, following a near 10% rally in the last three months. Options data from Barchart suggests an implied move of around 4% ahead of this week’s major event. (Barchart)

Thermo Fisher plans to report its fourth-quarter and full-year 2025 earnings before the market opens on Jan. 29. The company also scheduled a conference call for 8:30 a.m. ET that day, according to a statement. (Thermofisher)

U.S. stocks edged higher across the board, with the S&P 500 climbing roughly 0.6% and the Nasdaq gaining about 0.7%, boosting big healthcare and industrial firms. (Reuters)

Shares in the life-science tools sector edged higher. Danaher climbed roughly 1.0%, Agilent ticked up around 0.6%, and Waters inched up close to 0.2%.

According to analysts monitored by Barchart, based on Zacks estimates, Thermo Fisher is expected to earn roughly $6.43 per share in the December quarter, up from $6.10 a year ago. The data also projects full-year EPS at about $22.73 for 2025 and $24.58 for 2026. (Barchart)

Investors are keen to hear how management describes demand from pharmaceutical and biotech clients, and whether there’s any shift in spending on lab equipment, consumables, and outsourced services.

Investors will focus closely on Thermo Fisher’s guidance for 2026 margins and cash flow. Those details usually carry more weight than whether the company beats or misses its top-line forecast.

Expectations have climbed sharply following the recent rally. Any cautious signals, weaker order updates, or signs of slower growth could still drag the stock down, even if earnings beat forecasts.

Thursday’s earnings report and the 8:30 a.m. ET call are the next big events, with investors eager for more clarity on the 2026 outlook.

Stock Market Today

  • Sarepta Therapeutics Upgraded to Buy Amid Earnings Estimate Boost
    January 26, 2026, 1:44 PM EST. Sarepta Therapeutics (SRPT) received an upgrade to Zacks Rank #2 (Buy), reflecting improved earnings per share (EPS) estimates from analysts. The Zacks rating system is based solely on changes in earnings projections, a key indicator of near-term stock price movements. This upgrade signals rising institutional investor confidence, as higher earnings estimates typically lead to increased buying activity and share price gains. Sarepta's upgraded rating suggests a positive outlook for its business fundamentals. Tracking earnings estimate revisions remains crucial, with Zacks Rank #1 stocks historically delivering strong returns. Sarepta's upgrade reflects an expected improvement amid its current EPS projections.
Vale stock slides on Fabrica mine overflow in Brazil; what investors watch next
Previous Story

Vale stock slides on Fabrica mine overflow in Brazil; what investors watch next

USA Rare Earth (USAR) stock jumps as U.S. backs $1.6 billion CHIPS-linked funding plan
Next Story

USA Rare Earth (USAR) stock jumps as U.S. backs $1.6 billion CHIPS-linked funding plan

Go toTop